Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Long-Term Deferred Tax data on record, last reported at $71.1 million in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 33.56% year-over-year to $71.1 million; the TTM value through Sep 2025 reached $71.1 million, up 33.56%, while the annual FY2024 figure was $71.1 million, 33.56% up from the prior year.
  • Long-Term Deferred Tax reached $71.1 million in Q3 2025 per AMPH's latest filing, roughly flat from $71.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $71.1 million in Q4 2024 and bottomed at $22.0 million in Q3 2021.
  • Average Long-Term Deferred Tax over 5 years is $43.0 million, with a median of $40.9 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: decreased 10.33% in 2021, then skyrocketed 82.45% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $22.4 million in 2021, then soared by 72.0% to $38.5 million in 2022, then surged by 38.22% to $53.3 million in 2023, then skyrocketed by 33.56% to $71.1 million in 2024, then changed by 0.0% to $71.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $71.1 million in Q3 2025, $71.1 million in Q2 2025, and $71.1 million in Q1 2025.